What to Expect in Your First 90 Days on a GLP-1

The first 90 days on a GLP-1 medication like semaglutide or tirzepatide are the most important period of the entire therapy. This is when titration happens, when side effects peak and resolve, when patients form their habits around the medication, and when the early weight loss and metabolic improvements either build momentum or stall. What you experience in these three months will largely shape whether the therapy succeeds for you long-term.

Most patients arrive with vague expectations shaped by social media, friends’ experiences, and marketing materials. The actual first 90 days are more variable than any of these sources suggest. Here is what to expect, what is normal, what is concerning, and what good response looks like.

Week 1–4: Starting at the lowest dose

Both semaglutide and tirzepatide start at the lowest dose for the first four weeks regardless of patient size or eventual target dose. This is not arbitrary — the slow start exists specifically to let your body adapt to GLP-1 receptor activation gradually, minimizing the GI side effects that would otherwise occur with abrupt full-dose initiation.

For semaglutide, the starting dose is 0.25 mg weekly. For tirzepatide, the starting dose is 2.5 mg weekly. Both are administered by subcutaneous injection in the abdomen, thigh, or upper arm, on the same day each week.

At these starting doses, most patients notice some early effects within the first week. Appetite tends to drop noticeably — meals feel smaller, snacking impulses fade, and the mental space normally occupied by food thoughts starts to clear. Some patients describe this as “food noise” quieting down. Energy levels may shift, with some patients feeling more energetic and others feeling slightly tired in the first week or two.

Side effects also begin in this period. Nausea is the most common and is reported by roughly one in five patients during titration. It is typically mild at the starting dose, often described as queasiness rather than distinct nausea. Some patients experience early satiety so pronounced that meals must be restructured. A few patients have constipation or, less commonly, mild diarrhea. Most of these effects are most pronounced in the first 24-48 hours after the weekly injection and improve as the week progresses.

Week 5–8: The first dose increase

The standard titration schedule increases the dose at week 5. Semaglutide moves from 0.25 mg to 0.5 mg. Tirzepatide moves from 2.5 mg to 5 mg. This is when many patients experience their most pronounced side effects, because the dose has doubled and the body is adapting to a new level of receptor activation.

Nausea may increase. Some patients have brief vomiting episodes, particularly if they eat large or high-fat meals after the injection. Constipation can become more troublesome. Fatigue often peaks in this window. A small minority of patients experience headaches.

The good news is that these effects are predictable and time-limited. They typically resolve within two to three weeks of the dose increase as the body adjusts. The strategies that help include eating smaller meals, prioritizing protein and avoiding heavy fats and alcohol, staying well-hydrated, walking after meals, and timing the injection on a day when reduced food intake will not interfere with important activities.

For patients who find side effects intolerable at the standard titration pace, slower titration is reasonable. Staying at 0.25 mg semaglutide or 2.5 mg tirzepatide for an additional four weeks before advancing is a common adjustment that does not compromise long-term outcomes for most patients.

Week 9–12: The second dose increase and visible changes

The next dose increase typically arrives at week 9. Semaglutide moves to 1.0 mg. Tirzepatide moves to 7.5 mg. By this point, most patients are settling into a rhythm with the medication. Side effects from earlier titration steps have usually resolved. The new dose typically produces a mild rebound of side effects for one to two weeks before stabilizing.

This is also when meaningful weight loss usually becomes visible. Most patients have lost 4-8% of starting body weight by week 12, with substantial individual variation. Faster losers may have lost 10% or more. Slower responders may have lost 2-3%. Both ends of this range are within normal response patterns.

Body composition during this period matters. Significant rapid weight loss without adequate protein intake and without resistance training tends to include meaningful muscle loss along with fat loss. This is not unique to GLP-1 medications — any rapid weight loss has this problem — but it is particularly relevant when appetite suppression makes adequate protein intake harder to achieve.

The minimum protein target during weight loss is typically 1.2 to 1.6 grams per kilogram of target body weight, daily. For most adults this means 90-130 grams of protein per day. Achieving this with reduced appetite requires intentional planning: protein-forward meals, protein supplementation if needed, and sometimes protein-rich snacks even when not hungry.

Lab work and monitoring

Baseline labs before starting any GLP-1 medication include fasting glucose, HbA1c, comprehensive metabolic panel, lipid panel, TSH, and a brief medical history review with attention to pancreatitis history, gallbladder disease, family history of medullary thyroid cancer or MEN-2 syndrome, and current medications.

The first follow-up lab work typically occurs around 90 days into therapy. Expected changes at this point include modest improvements in fasting glucose and HbA1c (more pronounced in patients with elevated baseline values), modest improvements in triglycerides, and stable or improved liver function tests. Some patients show changes in kidney function markers due to weight loss and changed fluid status — usually benign but worth noting.

Ongoing monitoring includes weight at each visit, blood pressure (which often improves with weight loss), patient-reported symptoms and tolerability, and screening questions about pancreatitis warning signs (severe persistent abdominal pain) and gallbladder symptoms (right-upper-quadrant pain after meals).

What good response looks like

By the end of 90 days, patients responding well to GLP-1 therapy typically have:

Weight loss in the 5-10% range of starting body weight, with most of this being fat mass if protein intake and activity have been maintained. Patients on tirzepatide tend to be at the higher end of this range; patients on semaglutide at the lower end.

Meaningful improvement in metabolic markers if elevated at baseline — HbA1c reduction of 0.5-1.5%, fasting glucose normalization, triglyceride improvement, blood pressure normalization in many patients.

A new relationship with food. The reduced appetite and altered food reward signaling often translate into different eating patterns: smaller portions, less frequent snacking, easier moderation of previously difficult foods, and reduced obsessive thinking about food.

Settled side effect profile. Most early GI symptoms have resolved or become manageable. Energy is stable. Sleep is typically maintained or improved.

What concerning response looks like

Some patterns warrant reassessment rather than persistent dose escalation:

Severe ongoing nausea and vomiting beyond week 8 may indicate the medication is not the right fit. Slowing titration, changing administration timing, or discontinuing for an alternative is reasonable.

No appetite suppression at all by week 4 is unusual and worth discussing. Some patients are non-responders for reasons that are not fully understood; others may benefit from a different agent.

Severe abdominal pain that does not resolve quickly requires evaluation for pancreatitis. This is rare but serious.

Right-upper-quadrant pain, especially after fatty meals, warrants evaluation for gallbladder disease. GLP-1 medications increase rates of gallbladder events, particularly during rapid weight loss.

Significant muscle weakness, fatigue, or hair shedding may indicate inadequate protein intake or excessive caloric restriction. The medications make undereating easy; this is sometimes problematic.

Setting realistic expectations

The first 90 days are an investment period. The patients who succeed long-term are typically those who use this period to build the structure that supports continued progress: regular protein-forward eating, consistent resistance training to preserve and build muscle mass, sleep and stress management, and understanding that GLP-1 therapy is not a temporary intervention but a sustained partnership with the medication that may continue for years.

Patients who treat the medication as a magic short-term fix typically rebound when discontinuing. Patients who treat it as a tool that makes other healthy patterns achievable typically maintain the benefits over years. The first 90 days are when these patterns are established. Use them well.